Interaction of PPARα With the Canonic Wnt Pathway in the Regulation of Renal Fibrosis

Overview

Journal Diabetes

Specialty Endocrinology

Date 2016 Aug 21

PMID 27543085

Citations 40

Authors

Rui Cheng

Lexi Ding

Xuemin He

Yusuke Takahashi

Jian-Xing Ma

Affiliations

Soon will be listed here.

Abstract

Peroxisome proliferator-activated receptor-α (PPARα) displays renoprotective effects with an unclear mechanism. Aberrant activation of the canonical Wnt pathway plays a key role in renal fibrosis. Renal levels of PPARα were downregulated in both type 1 and type 2 diabetes models. The PPARα agonist fenofibrate and overexpression of PPARα both attenuated the expression of fibrotic factors, and suppressed high glucose-induced or Wnt3a-induced Wnt signaling in renal cells. Fenofibrate inhibited Wnt signaling in the kidney of diabetic rats. A more renal prominent activation of Wnt signaling was detected both in PPARα mice with diabetes or obstructive nephropathy and in PPARα tubular cells treated with Wnt3a. PPARα did not block the transcriptional activity of β-catenin induced by a constitutively active mutant of lipoprotein receptor-related protein 6 (LRP6) or β-catenin. LRP6 stability was decreased by overexpression of PPARα and increased in PPARα tubular cells, suggesting that PPARα interacts with Wnt signaling at the Wnt coreceptor level. 4-Hydroxynonenal-induced reactive oxygen species production, which resulted in LRP6 stability, was suppressed by overexpression of PPARα and dramatically enhanced in PPARα tubular cells. Diabetic PPARα mice showed more prominent NADPH oxidase-4 overexpression compared with diabetic wild-type mice, suggesting that the inhibitory effect of PPARα on Wnt signaling may be ascribed to its antioxidant activity. These observations identified a novel interaction between PPARα and the Wnt pathway, which is responsible, at least partially, for the therapeutic effects of fenofibrate on diabetic nephropathy.

Citing Articles

The Role of Wnt3a/β-Catenin/TCF7L2 Pathway in Diabetes and Cardiorenal Complications.

Adeerjiang Y, Sidike A, Gan X, Li Q, Jiang S Cardiorenal Med. 2024; 15(1):72-82.

PMID: 39709946 PMC: 11844670. DOI: 10.1159/000543145.

The crosstalk of Wnt/β-catenin signaling and p53 in acute kidney injury and chronic kidney disease.

Ming W, Wen L, Hu W, Qiao R, Zhou Y, Su B Kidney Res Clin Pract. 2024; 43(6):724-738.

PMID: 39558651 PMC: 11615452. DOI: 10.23876/j.krcp.23.344.

Blocking the WNT/β-catenin pathway in cancer treatment:pharmacological targets and drug therapeutic potential.

Zhao X, Ma Y, Luo J, Xu K, Tian P, Lu C Heliyon. 2024; 10(16):e35989.

PMID: 39253139 PMC: 11381626. DOI: 10.1016/j.heliyon.2024.e35989.

Ethyl Acetate Fractions of Bunge (Danshen) Crude Extract Modulate Fibrotic Signals to Ameliorate Diabetic Kidney Injury.

Hsu Y, Shih Y, Ho C, Liu C, Liaw C, Lin H Int J Mol Sci. 2024; 25(16).

PMID: 39201671 PMC: 11354680. DOI: 10.3390/ijms25168986.

Readily available drugs and other interventions to potentially improve the efficacy of immune checkpoint blockade in cancer.

Coleman M, Mascialino S, Panjwani A, Edwards E, Sukhatme V, Gavegnano C Front Immunol. 2024; 14:1281744.

PMID: 38299150 PMC: 10827885. DOI: 10.3389/fimmu.2023.1281744.

References

Lee K, Hu Y, Ding L, Chen Y, Takahashi Y, Mott R . Therapeutic potential of a monoclonal antibody blocking the Wnt pathway in diabetic retinopathy. Diabetes. 2012; 61(11):2948-57. PMC: 3478529. DOI: 10.2337/db11-0300. View

Desvergne B, Wahli W . Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999; 20(5):649-88. DOI: 10.1210/edrv.20.5.0380. View

Babelova A, Avaniadi D, Jung O, Fork C, Beckmann J, Kosowski J . Role of Nox4 in murine models of kidney disease. Free Radic Biol Med. 2012; 53(4):842-53. DOI: 10.1016/j.freeradbiomed.2012.06.027. View

Zhou T, He X, Cheng R, Zhang B, Zhang R, Chen Y . Implication of dysregulation of the canonical wingless-type MMTV integration site (WNT) pathway in diabetic nephropathy. Diabetologia. 2011; 55(1):255-66. DOI: 10.1007/s00125-011-2314-2. View

Lecarpentier Y, Claes V, Duthoit G, Hebert J . Circadian rhythms, Wnt/beta-catenin pathway and PPAR alpha/gamma profiles in diseases with primary or secondary cardiac dysfunction. Front Physiol. 2014; 5:429. PMC: 4220097. DOI: 10.3389/fphys.2014.00429. View

Duan S, Wu Y, Zhao C, Chen M, Yuan Y, Xing C . The wnt/β-catenin signaling pathway participates in rhein ameliorating kidney injury in DN mice. Mol Cell Biochem. 2015; 411(1-2):73-82. DOI: 10.1007/s11010-015-2569-x. View

Moldes M, Zuo Y, Morrison R, Silva D, Park B, Liu J . Peroxisome-proliferator-activated receptor gamma suppresses Wnt/beta-catenin signalling during adipogenesis. Biochem J. 2003; 376(Pt 3):607-13. PMC: 1223802. DOI: 10.1042/BJ20030426. View

Maretto S, Cordenonsi M, Dupont S, Braghetta P, Broccoli V, Hassan A . Mapping Wnt/beta-catenin signaling during mouse development and in colorectal tumors. Proc Natl Acad Sci U S A. 2003; 100(6):3299-304. PMC: 152286. DOI: 10.1073/pnas.0434590100. View

Liu G, Bafico A, Harris V, Aaronson S . A novel mechanism for Wnt activation of canonical signaling through the LRP6 receptor. Mol Cell Biol. 2003; 23(16):5825-35. PMC: 166321. DOI: 10.1128/MCB.23.16.5825-5835.2003. View

10.

Lee Y, Han H . Troglitazone ameliorates high glucose-induced EMT and dysfunction of SGLTs through PI3K/Akt, GSK-3β, Snail1, and β-catenin in renal proximal tubule cells. Am J Physiol Renal Physiol. 2009; 298(5):F1263-75. DOI: 10.1152/ajprenal.00475.2009. View

11.

Li Y, Lu W, He X, Bu G . Modulation of LRP6-mediated Wnt signaling by molecular chaperone Mesd. FEBS Lett. 2006; 580(22):5423-8. DOI: 10.1016/j.febslet.2006.09.011. View

12.

Guan Y, Breyer M . Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int. 2001; 60(1):14-30. DOI: 10.1046/j.1523-1755.2001.00766.x. View

13.

Raptis A, Viberti G . Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes. 2001; 109 Suppl 2:S424-37. DOI: 10.1055/s-2001-18600. View

14.

Thomas M, Bayha C, Vetter S, Hofmann U, Schwarz M, Zanger U . Activating and Inhibitory Functions of WNT/β-Catenin in the Induction of Cytochromes P450 by Nuclear Receptors in HepaRG Cells. Mol Pharmacol. 2015; 87(6):1013-20. DOI: 10.1124/mol.114.097402. View

15.

Brownlee M . The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005; 54(6):1615-25. DOI: 10.2337/diabetes.54.6.1615. View

16.

Logan C, Nusse R . The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004; 20:781-810. DOI: 10.1146/annurev.cellbio.20.010403.113126. View

17.

Molitch M, DeFronzo R, Franz M, Keane W, Mogensen C, Parving H . Nephropathy in diabetes. Diabetes Care. 2003; 27 Suppl 1:S79-83. DOI: 10.2337/diacare.27.2007.s79. View

18.

Surendran K, Schiavi S, Hruska K . Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J Am Soc Nephrol. 2005; 16(8):2373-84. DOI: 10.1681/ASN.2004110949. View

19.

Estacio R, Schrier R . Diabetic nephropathy: pathogenesis, diagnosis, and prevention of progression. Adv Intern Med. 2001; 46:359-408. View

20.

Racusen L, Monteil C, Sgrignoli A, Lucskay M, Marouillat S, Rhim J . Cell lines with extended in vitro growth potential from human renal proximal tubule: characterization, response to inducers, and comparison with established cell lines. J Lab Clin Med. 1997; 129(3):318-29. DOI: 10.1016/s0022-2143(97)90180-3. View